Sponsor

Universitaet Muenster

Germany Schlossplatz 2, Schlossbezirk, 48149 Munster, Germany

About the sponsor

Research activity includes diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular lymphoma, and high-grade B-cell lymphoma, with a strong focus on advanced treatment strategies for relapsed or refractory disease. The portfolio also extends to CAR T-cell therapy and other immune-based approaches in aggressive lymphoid cancers.

Diffuse large B-cell lymphoma (DLBCL)
Primary mediastinal large B-cell lymphoma (PMBCL)
Follicular lymphoma grade 3B
High-grade B-cell lymphoma (HGBL)

Investigations in this area also address treatment resistance and response assessment in relapsed/refractory lymphoma.

About Specializations

Universitaet Muenster runs clinical trials in conditions such as Acute kidney injury, Diffuse large B-cell lymphoma, Follicular lymphoma, High-grade B-cell lymphoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

14 clinical trials

Acute kidney injury+2

Recruiting

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Malic acid
Sponsor:Universitaet Muenster

Contact Research Centre

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Neuroblastoma+3

Recruiting

Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

InvestigationalNo placebo

Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:GD2IL18CART
Sponsor:Universitaet Muenster

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

Registered drugNo placebo

Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Universitaet Muenster

Contact Research Centre

Cardiac function disturbance postoperative+1

Recruiting

Study on Reducing Acute Kidney Injury After Heart Surgery Using Angiotensin II or Noradrenaline for Patients with Low Blood Pressure

Registered drugNo placebo

Study on Reducing Acute Kidney Injury After Heart Surgery Using Angiotensin II or Noradrenaline for Patients with Low Blood Pressure

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Angiotensin II
Sponsor:Universitaet Muenster

Contact Research Centre

Lymphangiosarcoma+34

Recruiting

Study of trabectedin alone versus trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

InvestigationalNo placebo

Study of trabectedin alone versus trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ttf-Ngr
Sponsor:Universitaet Muenster

Contact Research Centre

Neuroblastoma+2

Recruiting

Study on the Safety and Dosage of GD2IL18CART for Patients with Relapsed or Refractory GD2 Positive Solid Cancers

Registered drugNo placebo

Study on the Safety and Dosage of GD2IL18CART for Patients with Relapsed or Refractory GD2 Positive Solid Cancers

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anakinra
Sponsor:Universitaet Muenster

Contact Research Centre

Breast cancer+1

Recruiting

Study on Detecting Hidden Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ Using [68Ga]FAPI-46 and Gadobutrol

Registered drugNo placebo

Study on Detecting Hidden Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ Using [68Ga]FAPI-46 and Gadobutrol

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Gadobutrol
Sponsor:Universitaet Muenster

Contact Research Centre

Glioblastoma

Recruiting

A study of 5-aminolevulinic acid with radiotherapy (radiodynamic therapy) for patients with first recurrence of glioblastoma brain tumor

Registered drugNo placebo

A study of 5-aminolevulinic acid with radiotherapy (radiodynamic therapy) for patients with first recurrence of glioblastoma brain tumor

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Aminolevulinic Acid Hydrochloride
Sponsor:Universitaet Muenster

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo